MA54761A - Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif - Google Patents

Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif

Info

Publication number
MA54761A
MA54761A MA054761A MA54761A MA54761A MA 54761 A MA54761 A MA 54761A MA 054761 A MA054761 A MA 054761A MA 54761 A MA54761 A MA 54761A MA 54761 A MA54761 A MA 54761A
Authority
MA
Morocco
Prior art keywords
transsignaling
inhibitor
administration
selective
transsignaling inhibitor
Prior art date
Application number
MA054761A
Other languages
English (en)
Inventor
Ian Cottingham
Niclas Axel Petri
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA54761A publication Critical patent/MA54761A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
MA054761A 2014-12-01 2015-12-01 Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif MA54761A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086054P 2014-12-01 2014-12-01

Publications (1)

Publication Number Publication Date
MA54761A true MA54761A (fr) 2021-11-24

Family

ID=55305021

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41114A MA41114B1 (fr) 2014-12-01 2015-12-01 Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif
MA054761A MA54761A (fr) 2014-12-01 2015-12-01 Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41114A MA41114B1 (fr) 2014-12-01 2015-12-01 Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif

Country Status (19)

Country Link
US (2) US11198721B2 (fr)
EP (2) EP3226888B1 (fr)
JP (1) JP6775513B2 (fr)
KR (2) KR20170135819A (fr)
CN (1) CN107223132A (fr)
CA (1) CA2969301A1 (fr)
DK (1) DK3226888T3 (fr)
ES (2) ES2875351T3 (fr)
HR (1) HRP20210737T1 (fr)
HU (1) HUE054742T2 (fr)
LT (1) LT3226888T (fr)
MA (2) MA41114B1 (fr)
MD (1) MD3226888T2 (fr)
MX (1) MX2017007067A (fr)
PL (1) PL3226888T3 (fr)
PT (1) PT3226888T (fr)
RS (1) RS61947B1 (fr)
SI (1) SI3226888T1 (fr)
WO (1) WO2016087941A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240131465A (ko) * 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물
WO2019086463A1 (fr) 2017-10-30 2019-05-09 Baxalta GmbH Détergents compatibles avec l'environnement pour l'inactivation de virus enveloppés de lipides
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
MX2022015517A (es) * 2020-06-10 2023-01-16 Ferring Bv Compuesto farmaceutico para el tratamiento de la enfermedad cardiovascular aterosclerotica.
WO2022139580A1 (fr) 2020-12-22 2022-06-30 Ferring B.V. Biomarqueurs d'expression de gènes sanguins pour prédire une réponse chez des patients atteints de maladies intestinales inflammatoires
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
WO2024011946A1 (fr) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Dimères polypeptidiques pour le traitement de la sclérose systémique

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
WO2003008454A2 (fr) 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003024389A2 (fr) 2001-07-30 2003-03-27 Immunex Corporation Imx97018, polypeptide humain de type ataxine-1
JP2004182638A (ja) 2002-12-03 2004-07-02 Yakult Honsha Co Ltd 炎症性疾患又は悪性腫瘍の予防治療剤
EP1491554A1 (fr) 2003-06-23 2004-12-29 CONARIS research institute AG Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
EP1801121A1 (fr) 2005-12-23 2007-06-27 CONARIS research institute AG Variantes solubles de la molécule gp130 utiles comme médicament
CN101346395A (zh) * 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
DE602006016765D1 (de) * 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
EP2050759A1 (fr) 2007-10-19 2009-04-22 CONARIS research institute AG Mutéines gp 130 solubles dotées d'une activité de liaison améliorée
MX2013006234A (es) 2011-01-06 2013-08-01 Univ Johns Hopkins Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
KR20240131465A (ko) 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물

Also Published As

Publication number Publication date
LT3226888T (lt) 2021-05-25
JP6775513B2 (ja) 2020-10-28
SI3226888T1 (sl) 2021-08-31
EP3226888B1 (fr) 2021-04-21
CN107223132A (zh) 2017-09-29
DK3226888T3 (da) 2021-07-12
ES2875351T3 (es) 2021-11-10
PT3226888T (pt) 2021-06-02
HUE054742T2 (hu) 2021-09-28
RS61947B1 (sr) 2021-07-30
MD3226888T2 (ro) 2021-08-31
PL3226888T3 (pl) 2021-11-02
ES3068016T3 (es) 2026-05-27
KR20240166606A (ko) 2024-11-26
US20220135652A1 (en) 2022-05-05
JP2017537155A (ja) 2017-12-14
MA41114B1 (fr) 2021-06-30
HRP20210737T1 (hr) 2021-06-11
US11198721B2 (en) 2021-12-14
US20170320932A1 (en) 2017-11-09
WO2016087941A1 (fr) 2016-06-09
EP3912636B1 (fr) 2026-02-11
EP3912636A1 (fr) 2021-11-24
EP3226888A1 (fr) 2017-10-11
MX2017007067A (es) 2018-04-30
KR20170135819A (ko) 2017-12-08
CA2969301A1 (fr) 2016-06-09

Similar Documents

Publication Publication Date Title
NL301344I2 (nl) lnavolisib of een farmaceutisch aanvaardbaar zout daarvan
NL301208I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301364I2 (nl) sebetralstat of een farmaceutisch aanvaardbaar zout of solvaat daarvan
NL301128I2 (nl) Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
FIC20240030I1 (fi) Danikopaani tai sen farmaseuttisesti hyväksyttävä suola
NO2026006I1 (no) Elinzanetant or a pharmaceutically acceptable salt thereof
IL256018A (en) Audible indicator
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
ME03325B (fr) Inhibiteur de kinase aurora a
HUE057120T2 (hu) 3-izoxalidonok alkalmazása szelektív herbicidként
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
HUE053907T2 (hu) A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai
MA41116A (fr) Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
HUE054742T2 (hu) Szelektív IL-6-transz-szignalizációs inhibitor beadása
DK3445742T3 (da) Krystallin tapentadolphosphat
NL301306I2 (nl) Delgocitinib of een farmaceutisch aanvaardbaar zout daarvan
MA42689A (fr) Micropropagation d'un dattier t-r
DK3286190T3 (da) Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao)
FR3022281B1 (fr) Systeme d'habillage d'un grillage
EP3317836A4 (fr) Association d'un contexte